We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip to Main Content

VIRTUAL ISSUE: IMMUNE CHECKPOINTS IN CANCER


International Immunology presents a special virtual issue comprising Review articles published on immune checkpoints in cancer.

Full activation of T cells requires two signals: one via the TCR and one via an immune checkpoint that either co-stimulates or co-inhibits the TCR signal. Co-inhibitory molecules such as CTLA-4 and PD-1 thus prevent over-reaction by the immune system in normal circumstances. Unfortunately, tumors can subvert this mechanism to down-regulate immune attacks against them. 

Recently, spectacular success has been achieved in treating cancer using immunotherapeutic targeting of CTLA-4 and PD-1. CTLA-4 was first described in 1987 and was the first co-inhibitor to be characterized; the first description of PD-1 was by Tasuku Honjo and colleagues in 1992. In 2007, Taku Okazaki and Tasuku Honjo reviewed the progress to therapeutic manipulation of immune checkpoints in cancer. We have recently published several other review articles in the journal that update the enormous progress that has since been made in our knowledge of immune checkpoints in cancer.

Click on the article titles below to read free online. 

TABLE OF CONTENTS

PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki and Tasuku Honjo
Int. Immunol. (2007) 19 (7): 813-824

Therapeutic use of anti-CTLA-4 antibodies

Christian U. Blank and Alexander Enk
Int. Immunol. (2015) 27 (1): 3-10

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips and Michael Atkins
Int. Immunol. (2015) 27 (1): 39-46

Regulatory B cells in anti-tumor immunity
Yu Zhang, Nicolas Gallastegui, and Joseph D. Rosenblatt
Int. Immunol. (2015) 27 (10): 521-530

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
Stefani Spranger
Int. Immunol. (2016) in press [doi:10.1093/intimm/dxw014]

The role of neoantigens in response to the immune checkpoint blockade
Nadeem Riaz, Luc Morris, Jonathan J. Havel et al.
Int. Immunol. (2016) in press [doi:10.1093/intimm/dxw019]

Immune checkpoint inhibition in ovarian cancer
Junzo Hamanishi, Masaki Mandai, and Ikuo Konishi
Int. Immunol. (2016) in press [doi:10.1093/intimm/dxw020]

DID YOU ENJOY OUR FREE ARTICLE COLLECTION?





Continue to read International Immunology by purchasing a personal subscription or recommending the journal to your librarian today. Recommending International Immunology is easy. Complete our simple form and we’ll take it from there. 


Don't forget to sign up for journal e-alerts and stay up to date with articles as they publish online.
This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now